Save Product
Product Details
Source
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529).
Antibody Type
Recombinant Monoclonal
Clone
AM122
Isotype
Human IgG1, Kappa
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Application
ApplicationRecommended UsageELISA1:20000-1:200000Purification
Protein A purified / Protein G purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H2) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M122) with a linear range of 0.2-3 ng/mL (QC tested).
Protocol
Detection of SARS-CoV-2 S protein RBD by Sandwich ELISA Assay.<br> Immobilized Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M122) at 2 μg/mL (100 μL/well) can bind Spike RBD (Cat. No. SPD-C52H1). And then add Biotinylated Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM130) (Cat. No.S1N-M13L3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.05 ng/mL (Routinely tested).
Protocol
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat.No. S1N-M122) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Protocol
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat.No. S1N-M122) neutralizes SARS-CoV-2 (Omicron) Spike Trimer (Cat. No. SPN-C52Hz) by inhibiting Spike: ACE2 interaction. The ACE2-coated plate was incubated with the SARS-CoV-2 (Omicron) Spike Trimer protein and treated with neutralizing antibody at increasing concentration. Percent inhibition was calculated based on the OD value.
Protocol
Bioactivity-SPR
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M122) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 0.375 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
M***g2022-04-16
LikesOrdered S1N-M122 as a positive control for ACE2 competition experiments with a panel of SARS-CoV-2 variant RBDs. This antibody worked incredibly well, binding the tested variant RBDs with high affinity. Additionally, this antibody blocked 100% of ACE2 binding to the RBDs and when paired with S1N-M130 they serve as important competition controls to ensure that the RBDs and ACE2 are behaving as expected. Overall would highly recommend this product.
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
